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Mitochondrial dysfunction is a prominent feature of Alzheimer's disease (AD) and increased production of reac-
tive oxygen species (ROS) has been described in postmortem brain samples and animal models. However, these
observations weremade at a late stage of disease and the inability to examine an early, presymptomatic phase in
human neurons impeded our understanding of cause or consequence of mitochondrial dysfunction in AD. We
used human induced pluripotent stem cell-derived neuronal cells (iN cells) from sporadic AD (SAD) patients
and healthy control subjects (HCS) to show aberrant mitochondrial function in patient-derived cells. We ob-
served that neuronal cultures from some patients produced more ROS and displayed higher levels of DNA dam-
age. Furthermore, patient-derived cells showed increased levels of oxidative phosphorylation chain complexes,
whereas mitochondrial ﬁssion and fusion proteins were not affected. Surprisingly, these effects neither corre-
lated with Aβ nor phosphorylated and total tau levels. Synaptic protein levels were also unaffected in SAD iN
cells. The results of this study give new insights into constitutional metabolic changes in neurons from subjects
prone to develop Alzheimer's pathology. They suggest that increased ROS production may have an integral
role in the development of sporadic AD prior to the appearance of amyloid and tau pathology.
© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Alzheimer's disease is themost prevalent neurodegenerative disease
and characterized by the appearance of amyloid-plaques and neuroﬁ-
brillary tangles in the human brain (Winblad et al., 2016). AD is classi-
ﬁed in an early-onset, familial type (FAD) and a late-onset, sporadic
type, which represents about 95% of the cases (Winblad et al., 2016).
The cause for FAD are mutations in APP, PSEN1 or PSEN2, whereas the
underlyingmechanisms in SAD are still not clear. Genome-wide associ-
ation studies (GWAS) have identiﬁed a single nucleotide polymor-
phisms (SNPs) for SAD risk but provided little information about
biological processes (Nicolas et al., 2016). Further, dysregulation of an
entire pathway can be caused by mutations dispersed throughout the
genome, yet these might not be identiﬁed due to their different
locations. Induced pluripotent stem cells (iPSCs) offer a new venue to
AD research, not only due to the ability to model sporadic diseases but
also because they allow the use of human cells. Thus far, multiple stud-
ies used iPSC-derived neurons to assess AD pathology and possible
treatments. Drug testing was applied to elucidate mechanisms of APP
processing (Brownjohn et al., 2017; Mertens et al., 2013) and several
groups used iPSCs with familial AD mutations to show increased Aβ
production and tau phosphorylation (Moore et al., 2015; Woodruff et
al., 2013; Yagi et al., 2011) caused by these mutations. Two of the ﬁrst
studies using AD patient-derived neuronal cells were comparing SAD
to FAD-derived cells (Kondo et al., 2013; Israel et al., 2012). Israel and
colleagues used lines from two patients with APP duplications and
two SAD patients with one SAD line behaving like non-demented con-
trols and the second line similar to FAD lines, in regard toAβ production,
p-tau and active GSK-3-β levels. Kondo et al. used two different familial
mutations and SAD patient cells. APP-E693Δ and one SAD line showed
higher ROS levels and intracellular Aβ.
Mitochondrial dysfunction such as increased oxidativemtDNA dam-
age (Hirai et al., 2001; Mecocci et al., 1994) or higher cytochrome oxi-
dase levels (Hirai et al., 2001; Nagy et al., 1999) have been
hypothesized to be the potential causes of oxidative stress in AD brains.
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Also, an increase of mitochondrial ﬁssion protein Fis1 with concurrent
downregulation of Drp1 and fusion proteins Mfn1/2 and OPA1 has
been reported (Wang et al., 2009). In mouse models of familial AD re-
duced oxidative and complex I activity has been found (Derungs et al.,
2017; Rhein et al., 2009; Trushina et al., 2012), aswell as impaired com-
plex III and IV activity (Rhein et al., 2009; Caspersen et al., 2005).
Whereas a contradicting report found higher mRNA levels of complex
I, III, IV and V in the cortex of Tg2576 mice (Reddy et al., 2004). Obser-
vations in triple transgenic mice showed increased oxidative stress
levels prior to plaque deposition (Yao et al., 2009). In conclusion, mito-
chondrial dynamics and function are affected in AD, yet it remains difﬁ-
cult to delineate a clear mechanism due to a lack of human material to
examine an early time point of the disease and because ﬁndings in
mouse models might be affected by overexpression artifacts (Saito et
al., 2014; Saito et al., 2016).
Where prior studies focused on Aβ-mediated pathology, we aimed
to examine mitochondrial dysfunction at an early stage of disease. In
this study we show that iPSC-derived induced neuronal cells from
SAD patients show in part increased ROS production and display higher
levels of oxidative phosphorylation chain (oxphos) complexes. These
effects did not correlate with Aβ and tau levels.
2. Materials and methods
2.1. Culture and reprogramming of human ﬁbroblasts
Fibroblastswere obtained from skin biopsies. Samples were reduced
to small pieces and plated in hFib medium (DMEM (ThermoFisher Sci-
entiﬁc) + 10% FCS + 2 ng/ml bFGF (Peprotech)). Fibroblasts were
split by trypsination and transduced with reprogramming plasmids at
passage 3 (P3). A total of 1 μg of plasmids pCXLE-hUL, pCXLE-hSK and
pCXLE-hOCT3/4-shp53-F (Addgene: 27,080, 27,078, 27,077) (Okita et
al., 2011) were delivered by nucleofection with the Neon transfection
system (ThermoFisher Scientiﬁc) to 105 cells using the following set-
tings: 950 V, 40 ms, 2×. Cells were plated in hFib medium supple-
mented with 0.1 μM sodium butyrate (Sigma). Medium was changed
every other day. On day 7 cells were replated on growth factor reduced
matrigel (200 μg/ml, Corning) in hFib medium+ 0.1 μM sodium buty-
rate + 2 μM Thiazovivin(Sigma). Next day medium was changed to
E7 (Stemcell Technologies) (Chen et al., 2011) +0.1 μM sodium buty-
rate and changed every other day until d21. iPSC colonies were picked
under a stereomicroscope and expanded in E8 medium (ThermoFisher
Scientiﬁc) (Chen et al., 2011). Ten colonies of each patient and control
subject were picked and characterized (see Fig. 1 and Fig. S1) and two
of these colonies (clones) were used for subsequent experiments to ac-
count for clonal variation. Main ﬁgures show the data of two clones
pooled to represent the changes in a patient or control subject. Data
for individual clones are displayed in the supplementary ﬁgures.
2.2. Maintenance of iPSCs
IPSCs weremaintained in E8-ﬂexmedium (ThermoFisher Scientiﬁc)
on growth factor reduced matrigel (Corning). Cells were split once to
twice a week with ReLeSR (StemCell Technologies), according to man-
ual. All iPSC lines were tested negative for mycoplasma.
2.3. Differentiation of iPSCs to iN cells
Cells were differentiated according to Zhang et al. (Zhang et al.,
2013), with slight modiﬁcations. On day −2 iPSCs were dissociated
with Accutase (ThermoScientiﬁc) and 9–20 × 104 cells (depending sur-
vival of the cell line) plated on matrigel coated coverslips in a 24-well
plate in E8 supplementedwith Thiazovivin (2 μM, Sigma). Cellswere in-
fected with lentiviruses expressing rtTA and Neurogenin2 on day−1 in
fresh E8 medium. On day 0 mediumwas changed to induction medium
(DMEM/F12 (ThermoScientiﬁc) with doxycyclin (2 μg/ml), 1× N2
(ThermoFisher), 1× NEAA (Sigma), BDNF (10 ng/ml, Peprotech), NT-3
(10 ng/ml, Peprotech) and Laminin (200 μg/ml, Sigma)). On day 1,
induction medium was changed and supplemented with Puromycin
(1 μg/ml, Sigma) for a 24 h selection period. On day 2, 70.000 glia cells
were added in iN-Neurobasal medium (Neurobasal-A (ThermoFisher)
with 1× B27 (Gibco), 2 mM Glutamax (Gibco), 2 μM AraC (Sigma),
2 μg/ml Doxycyclin, 10 ng/ml BDNF, 10 ng/ml NT-3, and 200 μg/ml
Laminin)). 50% of the medium was changed every other day until
day 10, when medium was changed to Neuronal medium (MEM
(ThermoFisher), 1× B27, 0.5% Glucose, 0.02% NaHCO3, 100 μg/ml Trans-
ferrin (Sigma), 5% FCS, 0.5 mM L-glutamine and 2 μM AraC). Neuronal
medium was changed twice a week until cells were assayed on day
21–day 23.
2.4. Glia preparation and maintenance
Glia cells were prepared from P1 wild-type CD1 pups as followed.
Brain was extracted, meninges removed and forebrain isolated. Fore-
brains were digested in 10 U/ml papain for 30 min and cells dissociated
by pipetting. Cells were plated in DMEMwith 10% FCS in t75 ﬂasks. Glia
were split 1:3 with trypsin at 80% conﬂuence. Glia was used for co-cul-
tures between passages 2–4.
2.5. Lentiviral production
HEK293T cells were maintained in DMEM with 10% FCS and split
every other day by trypsination. Lentiviral vectors including three
helper plasmids were delivered by calcium phosphate transfection
(Chen & Okayama, 1987). In brief, 5 × 107 cells per 15 cm dish were
plated for transfection. 12.5 μg VSV-G, 25 μg pMDLg/pRRE, 12.5 μg
pREV and 50 μg plasmid of interest were mixed with 625 μl 0.5 M
CaCl2 and 625 μl H2O. Mixture was added dropwise to 1250 μl 2× HBS
on a vortexer, incubated for 30 mins at RT and added to cells. Medium
was changed the next morning and supernatant harvested after 48 h.
Lentivirus was concentrated by centrifugation (25,000 g for 90min), re-
suspended overnight in 200 μl E8 and snap frozen in liquid nitrogen. 0.2
μl lentiviral solution were used per 24-well. Lentivirus was produced
from the following plasmids: TetO-Ngn2-P2A-puromycin, rtTA, TetO-
EGFP, and synapsin-NLS-mCherry. All plasmids were a generous gift
from Prof. Thomas C. Südhof, Stanford University.
2.6. ROS assay
To increase cellular stress, iN cells were cultured in the absence of
B27 for 3 days prior to the experiment. On DIV21 cells were treated
with 5 μM CellRox green reagent (ThermoFisher) for 30 min at 37 °C
prior to ﬁxation. NeuN staining was carried out as described below
and coverslips imaged within 24 h. Fluorescent intensity was analyzed
by CellProﬁler Software (Carpenter et al., 2006) by measuring 488 nm
wavelength intensity in NeuN positive puncta (647 nm).
2.7. Analysis of DNA damage
Medium was changed two days prior to assay. On day 21, positive
control was treated with 5 μM Etoposide (Sigma) for 1 h, prior to ﬁxa-
tion. NeuN and p-γ-H2AX staining was carried out as described below.
Fluorescent intensity was analyzed by CellProﬁler Software by measur-
ing 488 nmwavelength intensity in NeuN positive puncta (647 nm).
2.8. Immunoﬂuorescence experiments
IN cells were ﬁxed in 4% paraformaldehyde in PBS for 20 min at RT.
Cells were washed 3× for 10 min with PBS and incubated for 1 h in
blocking buffer (10% donkey serum, 0.1% Triton X-100 in PBS). Primary
antibodywas incubated overnight at 4 °C in staining buffer (PBSwith 3%
goat serum and 0.1% Triton X-100). Subsequently cells werewashed 3×
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with PBS and secondary antibody applied in staining buffer for 1.5 h at
RT. Cells were washed once and incubated with DAPI for 20 min, then
washed 3× and mounted on cover slides. Immunoﬂuorescence was vi-
sualized on a Leica SP8 confocal microscope.
Antibodies used:
Primary AB Name Producer Cat. No. Dilution
Anti-Nanog R&D Af1997 1:100
Anti-TRA-1-60 Millipore MAB4360 1:100
Anti-NeuN Millipore MAB377 1:100
Anti-Synapsin Synaptic Systems 106,001 1:500
Anti-Map2 Synaptic Systems 188,003 1:600
Anti-γ-H2AX Abcam ab11174 1:500
Secondary AB Name Producer Cat. No. Dilution
Dk-α-ms-Alexa488 Jackson 715–545–151 1:250
Dk-α-rb-Alexa488 Jackson 711–545–152 1:250
Dk-α-gt-cy3 Jackson 705–165–147 1:250
Dk-α-ms-Alexa647 Jackson 715–606-151 1:250
Dk- α-rb-Alexa647 Jackson 711–605–152 1:250
2.9. Immunoblotting and protein quantiﬁcation
Cellswere harvested in RIPA buffer (50mMTris-HCl pH 7.6, 150mM
NaCl, 1% NP40, 0.5% SDS, 0.5% sodium deoxycholate, 2 mM EDTA) sup-
plemented with protease inhibitor (Roche) and phosphatase inhibitor
cocktail 1 and 3 (Sigma)), snap frozen in liquid nitrogen and stored at
−80 °C until use. Lysates were analyzed by SDS-Page on 10–20% Tris-
Tricine gels (ThermoFisher Scientiﬁc). Immunoblotting was performed
using peroxidase conjugated antibodies and detected with an
ImageQuant LAS 4000 system (GE Healthcare). Image analysis was car-
ried out in ImageJ. Signals were normalized to β-III-tubulin probed on
the same blot. Antibodies used:
Primary AB Name Producer Cat. No. Dilution
Anti-APP (Y188) Abcam ab32136 1:1000
Anti-β-III-tubulin Sigma T8660 1:500
Anti-Drebrin Cell Signaling 12,243 1:1000
(continued on next page)
Fig. 1. Fibroblast reprogramming to iPSCs and differentiation to iN cells. A Representative images of one control and one AD patient-derived iPSC line. IPSCs but not ﬁbroblasts showed an
embryonic stem cell-like morphology (DIC) and expressed the pluripotencymarkers Nanog (red) and Tra-1-60 (green). Reprogrammed cells retained a normal karyotype. Scale bar: 300
μm.BDifferentiation of iPSCs to iN cells. Overexpression of Ngn2 led to induction of neuronal-likemorphologyover the course of 21 days, visualized by EPFG expression. Imageswere taken
at 10×. C iN cells at day 21 stained positive for the neuronal marker Map2 (red) and the presynaptic marker synapsin (green). Scale bar: 200 μm (top), 25 μm (bottom).
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Anti-Drp1 (D6C7) Cell Signaling 8570S 1:1000
Anti-Phospho-Drp1 Cell Signaling 3455S 1:1000
Anti-Mfn1 Cell Signaling 13196S 1:1000
Anti-Mfn2 (D1E9) Cell Signaling 11925S 1:1000
Anti-Phospho-Tau (AT8) ThermoFisher MN1020 1:500
Anti-PSD-95 Millipore CP35 1:400
Anti-Synapsin Synaptic
Systems
106,001 1:1000
Anti-Tau Synaptic
Systems
314,004 1:1000
Anti-Total OXPHOS WB Antibody
Cocktail
Abcam ab110413 1:500
Secondary AB Name Producer Cat. No. Dilution
Anti-Mouse ECL IgG GE Healthcare NA931–1ML 1:4000
Anti-Rabbit ECL IgG GE Healthcare NA934V 1:4000
Anti-Guinea Pig IgG Jackson 106–035-003 1:4000
2.10. Gene expression analysis
Quantitative RT-PCR was performed to determine mRNA levels of
genes of interest. Total RNAwas isolated by TRI-Reagent (Sigma). Tech-
nical triplicates of each experimental condition were pooled and RNA
isolation was carried out according to manufacturer's instructions.
DNA was digested by DNaseI (Fermentas). 1 μg RNA was reverse-tran-
scribed to cDNA using the iScript cDNA-synthesis kit (BioRad), accord-
ing to manual. TaqMan probes with TaqMan Gene Expression Master
Mix (ThermoFisher Scientiﬁc) were used for expression analysis on a
7900HT Real-Time PCR System (ThermoFisher Scientiﬁc). Tubb3 was
used as an endogenous control. The assay ID of used TaqMan probes
was: human Tubb3, Hs00801390_s1; human GAPDH, Hs02786624_g1;
human Fis1, Hs00211420_m1; human Opa1, Hs01047018_m1.
2.11. MSD
Medium of iN cells was conditioned for 7 days and used for analysis.
Human Aβ38/40/42 was analyzed with the Aβ Peptide Panel 1 (6E10)
Kit (Meso Scale Discovery), according to manufacturer's instructions.
Individual values were normalized to neuron numbers determined by
dot blot assays probed against β-III-tubulin.
2.12. Karyotyping
Cells were arrested in metaphase by treatment with 80 ng/ml
colcemide for 1 h. Harvested and treated with hypotonic solution
(0.075 M KCl), followed addition of ﬁx solution (MeOH 3:1 Acetic
Acid). Metaphases spreadswere stained by Quinacrine (Sigma), imaged
on a Zeiss Axioskop HBO 50 ﬂuorescent microscope (Zeiss) and ar-
ranged in Ikaros Software (MetaSystems).
2.13. Quantiﬁcation and statistical analysis
Quantitative data represents means ± SEM. All experiments were
independently repeated at least three times (with the exception of the
ELISA assay which has been repeated twice). Statistical analyses were
conducted with by Prism (GraphPad Software). Statistical comparison
between multiple groups were analyzed by d'Agostino-Pearson omni-
bus normality test and subsequent one-way ANOVA with Tukey's test
for normal distributed date or Kruskal-Wallis test with Dunn's multiple
comparison post hoc test for non-normal distributed data. Statistical
signiﬁcance was only highlighted between control and patient-derived
cells.
2.14. Ethics approval
All performed experiments were conducted with the approval and
according to the regulations of the Cantonal Ethics Committee. Dermal
punch biopsies were taken following informed consent at the Clinic
for Dermatology of the University Hospital Zurich.
2.15. Conﬂict of interest
The authors declare that they have no conﬂict of interest.
3. Results
To address the mechanisms of oxidative stress and mitochondrial
dysfunction in SAD neuronal cells, we harnessed the iPSC technology
(Takahashi et al., 2007) to reprogram AD patient and HCS ﬁbroblasts
to pluripotency and differentiated those to induced neuronal cells (iN
cells) AD subjects were diagnosed according to standard diagnostic
criteria (McKhann et al., 2011), had a documented decline over time,
underwent complete clinical work up and neuropsychological testing
and had either positive amyloid-PET (11-C-PiB) signal or a typical CSF
constellation (Table 1). They were compared to HCSs from the same
age group with a negative amyloid-PET.
Fibroblast samples isolated from skin biopsies were reprogrammed
in feeder-free conditions (Chen et al., 2011) by delivery of episomal
plasmids (Okita et al., 2011). IPSC clones were analyzed for an embry-
onic stem cell-like morphology, normal karyotype and expression of
pluripotency markers Tra-1-60 and Nanog (Fig. 1A and Fig. S1). Two
clones per individual, positive for all criteria, were used for subsequent
analysis. Neuronal differentiation was carried out by lentiviral delivery
of doxycycline-inducible Neurogenin2 (Ngn2) expression (Zhang et
al., 2013). Neuronal cells underwent morphological changes over the
course of 21 days (Fig. 1B), expressed the neuronal marker Map2,
displayed synaptic boutons (Fig. 1C) and showed spontaneous activity
in calcium imaging (unpublished results). Cells were co-cultured with
mouse glia cells to support survival and synapse formation (Zhang et
al., 2013).
Various reports showwidespread changes inmitochondrial function
in AD. The production of ROS in mitochondria was found to be aug-
mented in AD human samples and mouse models (Mecocci et al.,
1994; Yao et al., 2009) and might play an integral role in disease
(Grimm et al., 2016). To analyze whether AD patient-derived neurons
display higher levels of oxidative stress than HCS neurons we used con-
focal imaging of CellRox green, a dye that increases ﬂuorescence upon
ROS-mediated oxidation. To avoid confounding with glia-derived ROS
we measured CellRox intensities in NeuN positive puncta. Menadione
treatment was used as a positive control for ROS production. Analysis
showed higher ROS levels in AD2, AD3, and AD4 iN cells showing statis-
tical signiﬁcance compared to both HCS's (Fig. 2A,B). Results of individ-
ual clones are shown in Fig. S2. These ﬁndings suggested altered
mitochondrial function in at least three out of ﬁve AD patients.
Table 1
Overview of recruited subjects for this study. Mean age at biopsy was 71.5 (HCS) and 74
(AD) with a range from 63 to 87 years. The individual age is not listed to avoid possible
identiﬁcation of the individuals as requested by the local ethics committee. n.d.: not
determined.
Diagnose ApoE PiB-PET SUVR Biomarker Gender
HCS1 – 3/3 1.07 n.d. Male
HCS1 – 3/4 1.17 n.d. Male
AD1 AD 3/3 n.d. Aβ: 550 pg/ml
P-Tau: 162 pg/ml
Total Tau: N1200 pg/ml
Female
AD2 AD 3/4 n.d. Aβ: 201 pg/ml
P- Tau: 160 pg/ml
Total Tau: 1094 pg/ml
Female
AD3 AD 3/4 2.4 n.d. Female
AD4 AD 3/4 2.16 n.d. Female
AD5 AD 3/3 2.42 n.d. Female
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Increased ROS productionmay be caused by dysfunctions of the mi-
tochondrial respiratory chain. Assessment of protein levels of oxphos
chain subunits are an indicator for altered complex function. Using an
oxphos antibody cocktail we showed higher NDUFB8 protein levels, a
subunit of oxphos complex I, in AD4 patient cells, compared to both
control lines (Fig. 3A,B). We further observed higher protein levels of
UQCRC2, a complex III subunit, in cells from AD4 and AD5 compared
to HCS1 (Fig. 3A,C). The most striking changes in oxphos chain compo-
sition were observed for MTOC1, a complex IV subunit. All AD-derived
iN cell lines had higher MTOC1 levels than HCS1, and AD4 and AD5 ad-
ditionally showed signiﬁcant higher MTOC1 levels than HCS2 (Fig. 3A,
D). Complex V subunit ATP5A showed higher protein amounts in AD2
and AD4 compared to HCS1 (Fig. 3A,E).
Misbalance in mitochondrial dynamics, i.e. fusion and ﬁssion, affects
mitochondrial integrity and may result in the observed changes in ROS
levels (DuBoff et al., 2013). Thus we assessed whether mitochondrial
ﬁssion and fusion protein levels were altered in AD patient-derived iN
cells. Mfn1, Mfn2 and Opa1 regulate mitochondrial fusion. We used
western blotting to assess Mfn1 levels but did not observe an alteration
in AD-patient iN cells (Fig. 3F,G). Likewise we examined Mfn2 and
found no changes in patient cells (Fig. 3F,H). Opa1 mRNA levels, a pro-
teinmediatingmitochondrial innermembrane fusion,were determined
by q-RT-PCR. We found decreased mRNA levels in AD2 cells compared
to HCS1, whereas other cell lines showed comparable mRNA levels
(Fig. 3I). Regulators of mitochondrial ﬁssion are Drp1, its active from
phosphorylated-Drp1, and Fis1. We could not observed differences be-
tween HCS-derived and patient iN cells in regard to total Drp1 (Fig. 3J,
K) and phosphorylated-Drp1 protein levels (Fig. 3J,L). Further, q-RT-
PCR of Fis1 showed similar mRNA levels in control and patient cells
(Fig. 3M). Individual clones are depicted in Fig. S3. Examination ofmito-
chondrial function suggests that AD patient-derived iN cells, which are
supposed to mimick early changes in AD, are rather affected by altered
oxphos complex composition than by defects in mitochondrial
dynamics.
Aggregates of Aβ and tau are themajor hallmarks of AD and thought
to be themain driver of AD pathology. Evidence exists that both, Aβ and
tau, affect mitochondrial function and thereby may contribute to ROS
generation (Rhein et al., 2009; DuBoff et al., 2013). Therefore we exam-
ined whether AD-patient derived iN cells show differences in APP pro-
cessing, Aβ secretion, as well as tau and phospho-tau levels. We
further investigated whether these correlate with the observed
misregulation of mitochondrial proteins or increased ROS production
in AD patient iN cells. First we assessed levels of APP protein in iN
cells from HCS's and AD-patients. As expected from samples of sporadic
AD cases, no higher total APP levels could be observed, in fact AD5 APP
levels were lower compared toHCS2 (Fig. 4A,B). Amylogenic processing
of APP by β-secretase leads to the generation of C99 (β-CTF), whereas
α-processing generates C83 (α-CTF). We assessed if ratios and total
Fig. 2.ROS production inADpatient andHCS iN cells. A Representative confocal images (20×)of iN cells stainedwith CellRox green dye followedby immunostaining againstNeuN. CellRox
intensity was assessed in overlay with NeuN positive puncta using Cell Proﬁler software. Menadione 50 μM was used as positive control. B Quantiﬁcation of CellRox intensity. ROS
production was signiﬁcantly higher in AD2, AD3,and AD4 iN cells compared to HCS1 and HCS2. Scale bar: 200 μm. Data are means ± SEM (n = 14–22). Statistical signiﬁcance was
assessed by Kruskal-Wallis test (*p b 0.05; **p b 0.01; ***p b 0.001).
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abundance of these products were changed in AD-derived iN cells. We
detected slightly higher C99/C83 ratios in AD1 to HCS2 cells, other cell
lines showed no change in processing ratios (Fig. 4C). Absolute C99
and C83 levels did not differ between control and AD cells (Figs. 4D,E
and S4C,D). As further processing of C99 by γ-secretase (De Strooper,
2010) leads to production of different Aβ species, we examined the ra-
tios of Aβ42 to Aβ40 in HCS and AD-patient-derived iN cells. Superna-
tant of iN cells was conditioned for 7 days and subsequently used for
Fig. 3. Levels ofmitochondrial proteins andmRNA in iN cells fromHCS and ADpatients. A Assessment ofmitochondrial oxidative phosphorylation chain complex I, III, IV andV subunits by
western blot using oxphos antibody cocktail. B Complex I subunit NDUFB8 was elevated in AD4 iN cells. C Complex III subunit UQCRC2 was signiﬁcantly higher in AD4 and AD5 iN cells
compared to HCS1. DMTOC1, a complex IV subunit, was higher in all AD-patient-derived iN cells compared to HCS1 and higher in AD4 and AD5 cells to HCS2. E Complex V subunit ATP5A
levelswere higher in AD2 and AD4 compared toHCS1. FMitochondrial fusion proteinsMfn1 andMfn2 levelswere assessed bywestern blot. G Quantiﬁcation ofMfn1 protein levels and H
Mfn2 levels, both show no differences between HCS and AD-derived iN cells. I Level of OPA1mRNA, assessed by qRT-PCR, was lower in AD2 compared to HCS1 iN cells. J Fission protein
Drp1 and phosphorylated-Drp1 levels were assessed by western blot. K Quantiﬁcation showed no changes between HCS and AD-derived iN cells for total Drp1. L No changes were
observed in phosphorylated-Drp1 levels to total Drp1. M Levels of FIS1 mRNA were assessed by RT-qPCR and showed no difference between HCS and AD patient-derived iN cells. Data
are means ± SEM (n= 8–12). Statistical signiﬁcance was assessed one-way ANOVA test (G-I; K-M) or by Kruskal-Wallis test (B-E) (*p b 0.05; **p b 0.01; ***p b 0.001).
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MSD analysis. Aβ42 is regarded as themost toxic species and its ratio to
Aβ40 is an essential determinant of amyloid aggregation in AD
(McGowan et al., 2005). MSD analysis showed no difference in Aβ42
to 40 ratios, except for cells from patient AD3, which displayed a
lower ratio compared to HCS1 (Fig. 4F). Analysis of absolute Aβ levels
showed higher total Aβ40 and 42 in AD5 iN cells compared to HCS2
and lower levels of Aβ40 and Aβ42 in AD3 compared to HCS1 (Fig.
S4E,F). Analysis of total and phosphorylated tau bywestern blot showed
no differences between AD and HCS iN cells (Fig. 4G–I and S4G,H).
Taken together, APP processing and tau modiﬁcation are not altered in
AD patient iN cells. The increase in total Aβ levels in the AD5 cell lines
does not correlate with the ﬁndings of ROS formation in AD cells, as
AD5 iN cells did not show increased ROS levels.
Oxidative stress and dysregulation of mitochondrial proteins can in-
duce downstream effects, such as DNA damage (Quiros et al., 2016) or
synaptic dysfunctions (Kamat et al., 2016). Phosphorylation of histone
H2AX has been identiﬁed as marker of DNA double-strand breaks
(Rogakou et al., 1998). Immunocytochemistry of phosphorylated γ-
H2AX in neuronal nuclei, stained by NeuN, revealed slight but signiﬁ-
cantly higher DNA damage in iN cells from patient AD2 and AD4 com-
pared to HCS2 but not to HCS1 (Fig. S5A,B).
Loss of synapses is the best correlate to the onset of cognitive decline
in AD (Terry et al., 1991). We set out to examine levels of different pre-
and post-synaptic proteins in HCS and AD-derived iN cells. Levels of
synapsin1, a marker of the presynapse, was found to be similar in iN
cells from patients and controls (Fig. S6A–C). Analysis of PSD95, a
major scaffold in the postsynapse, showed lower levels in AD1 cells
compared to HCS2 (Fig. S6D–F). DrebrinA, an actin binding protein in-
volved in recruitment of PSD95 to postsynapses (Takahashi et al.,
2003) is downregulated in AD brains (Shim & Lubec, 2002). In line
with our previous results, comparison of patient and control lines
displayed no signiﬁcant changes in protein levels (Fig. S6G–I). Taken to-
gether, no major synaptic alterations between HCS's and AD patients
were found, suggesting that these alterations may depend on Aβ and
arise later in the disease (Birnbaum et al., 2015; Palop & Mucke, 2010).
4. Discussion
In this studywe examined disease pathology in iPSC-derived neuro-
nal cells from AD patients with a very high diagnostic certainty and
healthy control subjects (ﬁnd summarized results in Table 2). Using a
rapid neuronal differentiation protocol we were able to examine pure
human neuronal cells, without culture impurities from other human
cell types, in contrast to differentiation protocols which were used pre-
viously to examine SAD pathology (Kondo et al., 2013; Israel et al.,
2012). The use of iN cells allows investigation of early AD, before
onset of amyloid and tau pathology. We showed that some patient-de-
rived iN cells display increased ROS production and aberrant mitochon-
drial complex composition, which did not correlate with Aβ, tau or p-
tau levels. Our ﬁndings suggest a strong involvement of altered
Fig. 4. Characterization of AD hallmark proteins in HCS and AD patient-derived iN cells. A Protein levels of APP and α- and ß-secretase processing products C83 and C99, determined by
western-blot. B Quantiﬁcation of APP levels. HCS2 APP levels were signiﬁcantly higher compared to AD5. C Quantiﬁcation of C99 to C83 ratios. Ratio was shifted toward C99 in AD1
compared to HCS2. D,E Quantiﬁcation of absolute C99 and C83 levels with no difference in AD and HCS-derived cells. n = 12–16; three independent experiments. F Analysis of Aβ42
to Aβ40 secretion of iN cells. Supernatant was conditioned from d21 to d28 and Aβ levels were subsequently measured by MSD. Aβ42 to 40 ratio is lower in AD3 compared to HCS1. G
Assessment of total and phosphorylated tau levels by western blot. H Quantiﬁcation of total tau levels in patient and control-derived iN cells. I Quantiﬁcation of phosphorylated tau to
total tau levels. I,J n = 12–18; Data are means ± SEM. Statistical signiﬁcance was assessed by Kruskal-Wallis test (*p b 0.05; **p b 0.01).
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mitochondrial function in early AD. Increased ROS levels have been ob-
served in various AD models (Rhein et al., 2009; Reddy et al., 2004;
Hauptmann et al., 2009; Hyun et al., 2010) and were found to be impli-
cated in other neurodegenerative processes (Busciglio & Yankner, 1995;
Liu et al., 2015; Zhao & Zhao, 2013). ROS production often promotes
DNA damage and vice versa (Quiros et al., 2016) and we also observed
increased DNA damage in our samples. The relation between ROS and
DNA damage is supported by the ﬁnding that the AD cell lines with
highest ROS levels also showed the highest degree of DNA damage.
We further analyzed the composition of the mitochondrial oxidative
phosphorylation chain, with complex I and III of the respiratory chain
being the main sites of ROS production. We found an upregulation of
complex IV subunit MTOC1 in all and upregulations of complex I, III,
and V in certain AD-derived iN cells. Cells from patient AD4 showed
higher levels of complex I and III, which could explain the increased
ROS levels. However, in AD2 and AD3 patient-derived iN cells, which
also showed increased ROS production, no changes in these complexes
were seen. Thus, ROS production heremight be caused by an alternative
mechanism,with complex IV upregulation as part of an oxidant defense
mechanism (Turrens, 2003). The changes in oxphos protein levels were
in linewith reports showing anupregulation in complex I, III, IV andV in
brains of AD patients (Nagy et al., 1999) and Tg2576 mice (Reddy et al.,
2004), whereas contradicting reports found lower levels of cytochrome
C oxidase (COX) in complex IV (Bosetti et al., 2002; Perez-Gracia et al.,
2008).We argue that our ﬁndings of complex IV upregulation may rep-
resent compensatorymechanisms, in order to account for reduced func-
tionality. Mitochondrial ﬁssion and fusion abnormalities by assessment
ofMFN1/2, OPA1, DRP1, phosphorylated-DRP1 and FIS1 levels could not
be detected in our samples, with the exception of AD2 cells showing
lower OPA1 mRNA levels. Previous studies reported reduced OPA1,
MFN1, andMFN2 levels and higher FIS1 levels in humanADbrain tissue.
Drp1 analysis has been reported to be lower in AD tissue in one study
and higher levels in another (Wang et al., 2009; Manczak & Reddy,
2012). As we observed a stronger effect on complex dysregulation
than changes in ﬁssion and fusion, we speculate that these changes in
AD brains may arise later in disease and are not visible at an early
stage. Examination of APP processing is in line with prior observations
that familial AD patients suffer from increased APP levels (APP duplica-
tion) or increased Aβ production, whereas sporadic patients mostly
have normal APP and Aβ levels (Kondo et al., 2013; Israel et al., 2012).
Yet, the strongest risk factor for sporadic AD ApoE4 has recently been
linked with higher APP transcription in human stem cell-derived iN
cells (Huang et al., 2017). We can rule out ApoE derived effects in our
system, as mouse glia, that is used for co-cultures in our system, only
produces one ApoE isoform. Abnormal tau phosphorylation has been
linked with tangle formation and neurodegeneration (Alonso et al.,
1996; Tackenberg & Brandt, 2009; Tackenberg et al., 2013; Goedert et
al., 1989).We could not detect changes in tau phosphorylation,whereat
it is important to note that iPSC-derived iN cells only express 3R and no
4R tau (unpublished results), which does not reﬂect the situation in
adult neuronal cells (Sposito et al., 2015). We cannot rule out that epi-
genetic effects might have contributed to AD progression, which cannot
be detected in reprogrammed cells (De Jager et al., 2014; Lunnon et al.,
2014), or that some of the phenotypes we observed are due to
reprogramming induced mutations (Kilpinen et al., n.d.).
We are aware that this study is based on an in vitro system of pure
cortical neurons, in which cells are deprived of their physiological mi-
croenvironment. This has to be taken into account, especially when re-
sults shall be translated to the pathologic processes in patients or even
into potential clinical trials. However, this is currently the only tech-
nique allowing the analyses of human, patient-derived cells. Further,
AD is a complex disease in which also other cell types such as astrocytes
andmicroglia play a crucial role, as well as vascular deﬁcits (Derungs et
al., 2017; Paolicelli et al., 2017; Merlini et al., 2016). Systems based on
iPSC-derived cells will allow uncovering contributions of different cell
types to AD pathogenesis in a controlled fashion. Accordingly, tech-
niques for differentiation of iPSCs into other disease-relevant cell
types are currently under extensive research.
We cannot fully exclude that gender differences inﬂuenced the re-
sults obtain in our analyses. However, the following reasons make this
inﬂuence unlikely: i) We did not observe effects in all AD patients, i.e.
AD1 (female) cells did not differ from HCS1 or HCS2 (both males); ii)
Studies on mitochondria of male and female mice did not show differ-
ences in bioenergetics, oxidative stress and apoptosis (Sanz et al.,
2007); iii) Several iPS studies analyzing APP processing, Aβ production,
Tau phosphorylation, oxidative stress, caspase activation, calcium sig-
naling, electrophysiological properties or gene-expression patterns in
human neurons did not show gender-related effects, only general inter-
individual variations, similar to what we observed in our study (Kondo
et al., 2013; Israel et al., 2012; Duan et al., 2014; Hu et al., 2015).
Our study showing oxidative stress andmitochondrial aberrations in
iPSC-derived AD patient neuronal cells, which captures an early
Table 2
Summary of results comparing individual AD subjects (AD1-5) to HCS1 and HCS2.
AD1 AD2 AD3 AD4 AD5
vs. HCS1 vs HCS2 vs. HCS1 vs HCS2 vs. HCS1 vs HCS2 vs. HCS1 vs HCS2 vs. HCS1 vs HCS2
ROS levels ↔ ↔ ↑ ↑ ↑ ↑ ↑ ↑ ↔ ↔
Complex I protein levels ↔ ↔ ↔ ↔ ↔ ↔ ↑ ↑ ↔ ↔
Complex III protein levels ↔ ↔ ↔ ↔ ↔ ↔ ↑ ↔ ↑ ↔
Complex IV protein levels ↑ ↔ ↑ ↔ ↑ ↔ ↑ ↑ ↑ ↑
Complex V protein levels ↔ ↔ ↑ ↔ ↔ ↔ ↑ ↔ ↔ ↔
Mfn1 protein levels ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
Mfn2 protein levels ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
OPA1 mRNA levels ↔ ↔ ↓ ↔ ↔ ↔ ↔ ↔ ↔ ↔
Drp1 protein levels ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
P-Drp1 protein levels ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
FIS1 mRNA levels ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
APP protein levels ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↓
Total Aβ 42 ↔ ↔ ↔ ↔ ↓ ↔ ↔ ↔ ↔ ↑
Total Aβ 40 ↔ ↔ ↔ ↔ ↓ ↔ ↔ ↔ ↔ ↔
Aβ42/40 ratio ↔ ↔ ↔ ↔ ↓ ↔ ↔ ↔ ↔ ↔
Total Tau protein levels ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
P-Tau protein levels ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
Synapsin protein levels ↔ ↓ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
PSD95 protein levels ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
Drebrin protein levels ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔
γ-H2AX intensity ↔ ↔ ↔ ↑ ↔ ↑ ↔ ↑ ↔ ↔
↑: signiﬁcant increase; ↓: signiﬁcant decrease;↔: no signiﬁcant differences.
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phenotype of thedisease, raises further questions. Amore in depth anal-
ysis ofmitochondrial changeswill be necessary to show if these changes
converge at a certain pathway and how this affects energy metabolism,
mitochondrial localization and transport, and ultimately neuronal func-
tion. Cellular mitochondrial changes might also exert effects on sur-
rounding tissue, creating a local dysregulated environment.
5. Conclusions
Prior studies using iPSC-derived neurons focused on Aβ- and tau-
mediated effects in SAD and FAD patient-derived cells (Kondo et al.,
2013; Israel et al., 2012). Here we reported increased ROS generation
and mitochondrial complex levels in patient-derived iN cells, which
does not correlate with Aβ or tau levels. Thus, these AD-relevant mito-
chondrial aberrations might have a causative role in disease develop-
ment in early stages preceding amyloid and tau pathology or they
might render cells more susceptible for Aβ- and tau-mediated neurode-
generation in later stages of the disease.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.scr.2018.01.019.
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